Abstract 226P
Background
The TREAP study is assessing the epidemiology and treatment patterns of non-metastatic NSCLC (Non-Small Cell Lung Cancer) in France in real life. We focus on stages III which encompass a wide range of clinical presentations leading to different treatment approaches.
Methods
This current analysis is a secondary data use of data collected from the KBP-2020 cohort. KBP-2020 is a Real-World French prospective study on lung cancer conducted in 82 non-academic public hospitals during the year 2020. Here, we describe patient and tumor characteristics of stage III NSCLC patients (pts) according to first therapeutic approach. The 8th TNM edition is used to define the stage.
Results
A total of 8299 pts were included in KBP-2020, 2903 pts (32,3%) with non-metastatic NSCLC and 1st line treatment available. Among these pts, 1425 were in stage III (49.1%): 649 stage IIIA, 556 stage IIIB and 220 stage IIIC. Comparison was made between resected pts (N=348) vs unresected pts (N=1077) according to stage. Among stage IIIA, 256 (39.4%)were resected. Resected pts were younger (mean age 66.4 (9.28) y. vs 69.7 (10.24) y.; they were less often active smokers (47.7% vs 55.1%), and more of them were ECOG PS 0–1 (95.2% vs 82.4%). 68.8% of resected stage IIIA pts vs 44.0% of unresected presented non squamous tumor; tumors PD-L1 expression and detection of oncogenic driver (EGFR, ALK or ROS1) were similar for resected and unresected patients. Among stage IIIB-C curative surgery was practiced for 92 (9.6%) patients. The first treatment approach including combination according to the sub-stage is described in the table. In resected stage III patients, 3-year survival was 61.5% [56.6–66.9] while it was 32.0% [29.3–34.9] in those not resected.
Table 226P| Treatments | Stage IIIA N=649 | Stage IIIB N=556 | Stage IIIC N=220 | |
| N curative surgery | 256 (39.4%) | 86 (15.5%) | 6 (2.7%) | |
| Curative | Exclusive | 50 | 21 | 3 |
| Surgery +/−RT | + neoadj. Chemo | 23 | 9 | 0 |
| + adj. Chemo | 125 | 30 | 3 | |
| Periop. Chemo | 7 | 6 | 0 | |
| N | 210 (32.4%) | 259 (46.6%) | 86 (39.1%) | |
| Curative RT without surgery | Exclusive (SBRT or standard) w/o ST | 18 | 12 | 1 |
| CRT cCRT | 137 | 186 | 60 | |
| sCRT | 43 | 50 | 18 | |
| CRT and 1O | 88 | 108 | 25 | |
| Systemic Therapy Without surgery/without RT | 136 (21.0%) | 164 (29.5%) | 107 (48.6%) | |
| Observation | 47 (7.2%) | 47 (8.5%) | 21 (9.5%) | |
cCRT concomitant, sCRT sequential - CRT, chemoradiotherapy; IO, immunotherapy; RT, radiotherapy; ST, systemic treatment.
Conclusions
This real-life study reflects the heterogeneous nature of stage III NSCLC and the multimodalities therapeutic approaches resulting from it.
Legal entity responsible for the study
MSD FRANCE.
Funding
MSD France.
Disclosure
C. Chouaid: Financial Interests, Personal, Advisory Board: AstraZeneca, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AstraZeneca, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. O. Bylicki: Financial Interests, Personal, Advisory Board, Expert Board: BMS, Roche, Takeda; Financial Interests, Personal, Other, Travel congress: MSD; Financial Interests, Personal, Advisory Board, expert board: AstraZeneca, Janssen; Financial Interests, Personal, Advisory Board, Board: MSD; Financial Interests, Personal, Other, Travel Congress: AstraZeneca. A. Spampinato: Financial Interests, Personal, Full or part-time Employment: MSD France; Financial Interests, Personal, Royalties: MSD France; Financial Interests, Personal, Licensing Fees: MSD France; Financial Interests, Personal, Other, Travel: MSD France; Financial Interests, Personal, Stocks/Shares: MSD France. N. Offner: Financial Interests, Personal, Full or part-time Employment: MSD France. A. Eberlin: Financial Interests, Personal, Full or part-time Employment: MSD France; Financial Interests, Personal, Other, travel: MSD France; Financial Interests, Personal, Royalties: MSD France; Financial Interests, Personal, Licensing Fees: MSD France; Financial Interests, Personal, Stocks/Shares: MSD France. D. Debieuvre: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Janssen, Sanofi-Winthrop, Amgen, Roche; Financial Interests, Personal, Invited Speaker: Takeda, Pfizer; Financial Interests, Institutional, Funding: Roche, AstraZeneca, Janssen, MSD, Pfizer, BMS, Lilly, Boehringer Ingelheim, GSK, Chugaï, Chiesi, Takeda, Bayer, Sanofi-Winthrop, Amgen, AbbVie.